There is no publicly available information detailing a class action lawsuit specifically targeting Onivyde. Class action lawsuits are legal actions brought on behalf of a large group of people who have experienced a similar harm. The absence of reports or case filings suggests that no such lawsuit is currently active or has been widely publicized.
What is Onivyde used for?
Onivyde is a chemotherapy drug used to treat pancreatic cancer. It is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [1]. Onivyde is indicated for use in combination with fluorouracil and leucovorin in patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy [1].
How does Onivyde work?
Onivyde works by delivering irinotecan, a potent chemotherapy agent, over a prolonged period. The liposomal encapsulation helps to prolong the circulation of the drug and allows for a higher concentration of irinotecan to reach tumor cells. Irinotecan inhibits topoisomerase I, an enzyme essential for DNA replication and cell division. By inhibiting this enzyme, irinotecan causes DNA damage and ultimately leads to the death of cancer cells [1].
Who manufactures Onivyde?
Ipsen Biopharmaceuticals is the company that markets Onivyde in the United States [1].
What is the patent status of Onivyde?
Information on the specific patents covering Onivyde and their expiration dates can be found through specialized drug patent tracking services. DrugPatentWatch.com provides detailed patent information for pharmaceuticals, which can include details on active patents, patent litigation, and anticipated patent expiry dates [2]. This information is crucial for understanding market exclusivity and the potential for generic competition.